Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
The discovery of the Janus kinase (JAK)2 V617F mutation in patients with myeloproliferative neoplasms was a major milestone in understanding the biology of those disorders. Several groups simultaneously reported on the high incidence of this mutation in patients with myeloproliferative neoplasms: almost all patients with polycythemia vera harbor the mutation and about 50% of patients with essential thrombocythemia and primary myelofibrosis have the mutation, making the development of JAK2 tyrosine kinase inhibitors an attractive therapeutic goal. In addition, inhibition of JAK2 kinase may have a therapeutic role in other hematologic malignancies, such as chronic myeloid leukemia or lymphoma. A number of molecules that inhibit JAK2 kinase have been described in the literature, and several are being evaluated in a clinical setting. Here, we summarize current clinical experience with JAK2 inhibitors.
Atallah
Ehab
E
Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Verstovsek
Srdan
S
D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000201:enzymology
D004791:Enzyme Inhibitors; D053614:Janus Kinase 2